






#### THE BENEFITS OF A SUSTAINABLE GENERIC MEDICINES INDUSTRY

# A VITAL PARTNER FOR HEALTH






High technology manufacturing employs 160,000 highly trained Europeans <sup>2</sup> and **75% of generic medicines are manufactured in Europe** <sup>3</sup>



## BUT A SUSTAINABLE GENERIC MEDICINES INDUSTRY NEEDS A BETTER FRAMEWORK







Arbitrary **price cuts threaten** the economic viability of manufacturers



"Payback taxes" disproportionately hurt generic manufacturers and undermine competition

### PRICING PRESSURE COMES WITH A VERY REAL COST










Increased risk of medicine shortages





Key medicines such as some antibiotics might **disappear from** market




Investment in life-saving medicines and off-patent innovation could dry up



A competitive multi-source market will prevent or mitigate shortages










Improve regulatory efficiency to reduce administrative and cost burden of keeping products in the market

#### Introduce specific measures such as improving e-leaflets and harmonisation of pack sizes



Ensure market predictability



0		
	_	
	_	
	_	

Improve available market stock information

#### REFERENCES 🔍

- 1 / About Medicines for Europe; Available from: http://www.medicinesforeurope.com/medicines-for-europe/
- 2 / About the Generic Medicines Group; Available from: http://www.medicinesforeurope.com/generic-medicines/who-we-are/
- 3 / Quintiles IMS Health, MIDAS, Q4 2014; OECD population statistics
- 4 / Paularusu.ro; OFICIAL: Medicamentele pentru cancer nu se mai vând în România! Programul electoral al PSD, program de exterminare pentru 1 milion de bolnavi; Available from:
- http://www.paularusu.ro/sanatate/oficial-medicamentele-pentru-cancer-nu-se-mai-vand-in-romania-programul-electorlal-al-psd-program-de-exter minare-pentru-bolnavii-de-cancer/

patients • quality • value • sustainability • partnership